News

In this article, Dr Tanna discusses treatment options for glaucoma patients who do not show satisfactory response to a PGA while taking into consideration the two key therapeutic choice factors: IOP-lowering efficacy and tolerability.

This follow-up study found anterior capsule opacification development and anterior capsule retraction to be more frequent 3 years after cataract surgery when an IOL with interrupted sharp optic edge at the optic–haptic junction is implanted, compared with an IOL with a continuous edge.

CO2 laser-assisted sclerectomy surgery performed with a proprietary platform offers an effective and safer alternative to the manual non-penetrating deep sclerectomy procedure for the management of medically uncontrolled open-angle glaucoma.

In this comparison study, IOP reductions were greater with BTFC than with TTFC and patients on this combination were more likely to achieve and maintain low target pressures. Combined BrTFC and DTFC may also be a more appropriate therapeutic choice for IOP lowering than TTFC and BrTFC, respectively.

One-year after implantation of the Cypass Micro-Stent, study results demonstrate a reduction in IOP and glaucoma medications, as well as a complete lack of sight-threatening adverse events. The implant is placed into the supraciliary space to facilitate suprachoroidal aqueous outflow in glaucoma patients.

Using a new metric seems to be an easy way to determine a patient’s risk of developing ectasia after a refractive procedure, according to Marcony R. Santhiago, MD, PhD.

Ophthalmologists are over-prescribing steroids to treat vernal keratoconjunctivitis (VKC) and causing an increase of steroid-induced glaucoma (SIG) in children, according to a recent study publish in the British Journal of Ophthalmology.

Learn about the effect of increased osmolarity on the corneal surface. This video provides insight into managing patients with hyperosmolarity and about the importance of testing in patients considering surgery.

In his latest blog, Mark Packer, MD, writes of a surgical tale that led him to discover aberrations can sometimes be your friend.

In preparation for U.S. News World & Report’s annual best ophthalmic hospitals for 2015-which will be announced next month-we have compiled the news site’s list of the top programs from last year. These 10 hospitals were coined the best for difficult cases and procedures by at least 5% of ophthalmology respondents to U.S. News’ surveys in 2012, 2013, and 2014.

The European Medicines Agency (EMA) has granted orphan drug designation to ISTH0036, a locked nucleic acid-modified antisense oligonucleotide under development by Munich-based Isarna Therapeutics, for the prevention of scarring after glaucoma filtration surgery (GFS).

Targeting the blood-vessel-growth protein angiopoietin-like 4 (ANGPTL4) along with anti-vascular endothelial growth factor (VEGF) therapy could increase the effectiveness of treatments for the prevention of proliferative diabetic retinopathy (PDR), according to researchers at The Johns Hopkins University and the University of Maryland.

As staff members develop in new roles, managers should coach and counsel them in the direction where they are thinking and making decisions in a global manner, not an individual manner.

The costs associated with medications for patients with glaucoma continue to have a significant effect on adherence. Making a switch from branded to generic drugs may make a difference for some patients in certain cases.

Reddit CEO Ellen Pao’s establishment of a new policy that no longer allows new hires to negotiate their salaries is attracting attention-and some praise.

Take-home message: When considering IOL implantation options when there is a lack of capsular support, cataract surgeons should use the approach with which they are most comfortable. They should also continue to learn about new available techniques.

Take-home message: The implantable collamer lens features several design enhancements that make the procedure more patient- and surgeon-friendly.

Fluid-based accommodating IOL technology achieved “true accommodation” in a pilot study. A multicenter study of the lens is ongoing.

Low-add multifocal IOL models improved near vision and increased spectacle independence while providing comparable distance vision and good safety outcomes.